CRIS Current Research Information System

MANCINI, MANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.699
AS - Asia 4.483
EU - Europa 2.964
AF - Africa 270
SA - Sud America 201
Continente sconosciuto - Info sul continente non disponibili 195
OC - Oceania 8
Totale 12.820
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.612
VN - Vietnam 1.536
SG - Singapore 1.157
CN - Cina 908
GB - Regno Unito 655
IT - Italia 527
DE - Germania 390
SE - Svezia 329
HK - Hong Kong 278
FR - Francia 176
NL - Olanda 170
IN - India 161
RU - Federazione Russa 153
BR - Brasile 136
IE - Irlanda 134
UA - Ucraina 132
TG - Togo 88
JP - Giappone 81
ZA - Sudafrica 69
FI - Finlandia 60
KR - Corea 56
BD - Bangladesh 52
CI - Costa d'Avorio 52
EE - Estonia 52
CA - Canada 43
JO - Giordania 40
CH - Svizzera 34
BG - Bulgaria 30
TH - Thailandia 29
NG - Nigeria 25
ID - Indonesia 23
IR - Iran 22
BE - Belgio 21
AR - Argentina 20
IQ - Iraq 20
EC - Ecuador 18
PL - Polonia 17
TW - Taiwan 17
MX - Messico 16
SA - Arabia Saudita 16
TR - Turchia 15
CZ - Repubblica Ceca 14
SC - Seychelles 14
ES - Italia 13
PH - Filippine 13
GR - Grecia 10
PK - Pakistan 10
VE - Venezuela 10
AT - Austria 9
UZ - Uzbekistan 9
AU - Australia 7
LT - Lituania 7
RO - Romania 7
CR - Costa Rica 6
HR - Croazia 6
JM - Giamaica 6
LB - Libano 6
MA - Marocco 6
MY - Malesia 6
NP - Nepal 6
CL - Cile 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
GT - Guatemala 4
DZ - Algeria 3
GE - Georgia 3
HN - Honduras 3
NO - Norvegia 3
PE - Perù 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BY - Bielorussia 2
DK - Danimarca 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
MD - Moldavia 2
MU - Mauritius 2
NI - Nicaragua 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
RS - Serbia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GH - Ghana 1
GI - Gibilterra 1
GY - Guiana 1
HU - Ungheria 1
KG - Kirghizistan 1
Totale 12.616
Salva come PNG Salva come JPEG
Città #
Singapore 843
Southend 566
Ashburn 503
Chandler 468
Ho Chi Minh City 386
Fairfield 349
San Jose 318
Hanoi 301
Hong Kong 262
Wilmington 192
Seattle 191
Houston 173
Woodbridge 170
Dong Ket 160
Beijing 152
Princeton 136
Dublin 134
Cambridge 131
Ann Arbor 122
Bologna 105
Santa Clara 104
Hefei 102
Council Bluffs 91
Lomé 88
Boardman 85
Jacksonville 79
Tokyo 66
New York 63
Los Angeles 61
Lauterbourg 60
Nanjing 60
Westminster 57
Abidjan 52
Padova 51
Helsinki 47
Berlin 46
Da Nang 42
Seoul 42
Milan 41
Redmond 40
Frankfurt am Main 39
Amman 35
San Diego 33
Chicago 32
Haiphong 31
Redondo Beach 31
Sofia 30
Shenyang 29
Medford 28
Bern 27
Buffalo 27
Jinan 27
Rome 25
Changsha 24
Saint Petersburg 24
Abeokuta 23
Biên Hòa 22
Ha Long 22
Munich 22
Turin 22
Dallas 21
Falkenstein 21
Brussels 20
Falls Church 20
Hebei 20
Tianjin 19
Nanchang 18
São Paulo 18
Florence 17
Guangzhou 17
Dearborn 16
London 16
Nuremberg 16
Phoenix 16
Zhengzhou 16
Atlanta 15
Bremen 15
Jiaxing 15
Shanghai 15
Toronto 15
Brooklyn 14
Johannesburg 14
Norwalk 14
Bengaluru 13
Montreal 13
Mülheim 13
Orem 13
Thái Nguyên 13
Jakarta 12
Taizhou 12
Bangkok 11
Can Tho 11
Des Moines 11
Washington 11
Xi'an 11
Baghdad 10
Hangzhou 10
Mountain View 10
Ninh Bình 10
Warsaw 10
Totale 8.074
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 667
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 295
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 278
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 271
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 248
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 236
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 230
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 222
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 215
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 214
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 212
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 200
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 192
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 190
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 189
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 189
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 188
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 186
C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. 183
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 180
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 178
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 177
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities 177
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 176
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 176
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 176
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 173
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 171
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 170
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 170
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 169
Best practices in chronic myeloid leukemia monitoring and management 168
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 167
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 167
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 166
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 165
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy 165
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 164
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 163
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. 161
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. 161
mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein 160
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 160
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 159
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 158
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 156
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 154
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 152
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 150
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 148
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 147
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 146
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 143
A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias 141
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 139
RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia 137
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort? 137
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 133
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 131
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 129
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 128
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 125
Present and future of molecular monitoring in chronic myeloid leukaemia. 124
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 123
Systemic mastocytosis: Molecular landscape and implications for treatment 123
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 122
Idetification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. 121
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 117
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia 115
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 114
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability 82
A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib 2
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3 sigma case. 2
Totale 12.820
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.513
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.513
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.121 0 24 76 80 116 76 28 86 57 85 248 245
2022/20231.631 184 262 87 197 118 127 58 72 279 41 133 73
2023/2024446 20 77 27 63 37 100 22 29 14 21 16 20
2024/20251.671 47 268 150 117 199 71 136 79 34 215 83 272
2025/20264.487 395 722 301 281 512 203 338 163 941 330 178 123
2026/2027235 91 144 0 0 0 0 0 0 0 0 0 0
Totale 12.820